Cargando…

Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study

The real-world effectiveness of the coronavirus disease 2019 (COVID-19) vaccines in Japan remains unclear. This case–control study evaluated the vaccine effectiveness (VE) of two doses of mRNA vaccine, BNT162b2 or mRNA-1273, against the delta (B.1.617.2) variant in the Japanese general population in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hara, Megumi, Furue, Takeki, Fukuoka, Mami, Iwanaga, Kentaro, Matsuishi, Eijo, Miike, Toru, Sakamoto, Yuichiro, Mukai, Naoko, Kinugasa, Yuki, Shigyo, Mutsumi, Sonoda, Noriko, Tanaka, Masato, Arase, Yasuko, Tanaka, Yosuke, Nakashima, Hitoshi, Irie, Shin, Hirota, Yoshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145554/
https://www.ncbi.nlm.nih.gov/pubmed/35632535
http://dx.doi.org/10.3390/vaccines10050779
_version_ 1784716344034328576
author Hara, Megumi
Furue, Takeki
Fukuoka, Mami
Iwanaga, Kentaro
Matsuishi, Eijo
Miike, Toru
Sakamoto, Yuichiro
Mukai, Naoko
Kinugasa, Yuki
Shigyo, Mutsumi
Sonoda, Noriko
Tanaka, Masato
Arase, Yasuko
Tanaka, Yosuke
Nakashima, Hitoshi
Irie, Shin
Hirota, Yoshio
author_facet Hara, Megumi
Furue, Takeki
Fukuoka, Mami
Iwanaga, Kentaro
Matsuishi, Eijo
Miike, Toru
Sakamoto, Yuichiro
Mukai, Naoko
Kinugasa, Yuki
Shigyo, Mutsumi
Sonoda, Noriko
Tanaka, Masato
Arase, Yasuko
Tanaka, Yosuke
Nakashima, Hitoshi
Irie, Shin
Hirota, Yoshio
author_sort Hara, Megumi
collection PubMed
description The real-world effectiveness of the coronavirus disease 2019 (COVID-19) vaccines in Japan remains unclear. This case–control study evaluated the vaccine effectiveness (VE) of two doses of mRNA vaccine, BNT162b2 or mRNA-1273, against the delta (B.1.617.2) variant in the Japanese general population in the period June–September 2021. Individuals in close contact with COVID-19 patients were tested using polymerase chain reaction (PCR). A self-administered questionnaire evaluated vaccination status, demographic data, underlying medical conditions, lifestyle, personal protective health behaviors, and living environment. Two vaccine doses were reported by 11.6% of cases (n = 389) and 35.2% of controls (n = 179). Compared with controls, cases were younger and had a lower proportion who always performed handwashing for ≥20 s, a higher proportion of alcohol consumers, and a lower proportion of individuals living in single-family homes or with commuting family members. After adjusting for these confounding factors and day of PCR testing by multivariate logistic regression analysis, the VE in the period June–July (delta variant proportion 45%) was 92% and 79% in the period August–September (delta variant proportion 89%). The adjusted VE for homestay, hotel-based isolation and quarantine, and hospitalization was 78%, 77%, and 97%, respectively. Despite declining slightly, VE against hospitalization remained robust for ~3 months after the second dose. Vaccination policymaking will require longer-term monitoring of VE against new variants.
format Online
Article
Text
id pubmed-9145554
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91455542022-05-29 Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study Hara, Megumi Furue, Takeki Fukuoka, Mami Iwanaga, Kentaro Matsuishi, Eijo Miike, Toru Sakamoto, Yuichiro Mukai, Naoko Kinugasa, Yuki Shigyo, Mutsumi Sonoda, Noriko Tanaka, Masato Arase, Yasuko Tanaka, Yosuke Nakashima, Hitoshi Irie, Shin Hirota, Yoshio Vaccines (Basel) Article The real-world effectiveness of the coronavirus disease 2019 (COVID-19) vaccines in Japan remains unclear. This case–control study evaluated the vaccine effectiveness (VE) of two doses of mRNA vaccine, BNT162b2 or mRNA-1273, against the delta (B.1.617.2) variant in the Japanese general population in the period June–September 2021. Individuals in close contact with COVID-19 patients were tested using polymerase chain reaction (PCR). A self-administered questionnaire evaluated vaccination status, demographic data, underlying medical conditions, lifestyle, personal protective health behaviors, and living environment. Two vaccine doses were reported by 11.6% of cases (n = 389) and 35.2% of controls (n = 179). Compared with controls, cases were younger and had a lower proportion who always performed handwashing for ≥20 s, a higher proportion of alcohol consumers, and a lower proportion of individuals living in single-family homes or with commuting family members. After adjusting for these confounding factors and day of PCR testing by multivariate logistic regression analysis, the VE in the period June–July (delta variant proportion 45%) was 92% and 79% in the period August–September (delta variant proportion 89%). The adjusted VE for homestay, hotel-based isolation and quarantine, and hospitalization was 78%, 77%, and 97%, respectively. Despite declining slightly, VE against hospitalization remained robust for ~3 months after the second dose. Vaccination policymaking will require longer-term monitoring of VE against new variants. MDPI 2022-05-14 /pmc/articles/PMC9145554/ /pubmed/35632535 http://dx.doi.org/10.3390/vaccines10050779 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hara, Megumi
Furue, Takeki
Fukuoka, Mami
Iwanaga, Kentaro
Matsuishi, Eijo
Miike, Toru
Sakamoto, Yuichiro
Mukai, Naoko
Kinugasa, Yuki
Shigyo, Mutsumi
Sonoda, Noriko
Tanaka, Masato
Arase, Yasuko
Tanaka, Yosuke
Nakashima, Hitoshi
Irie, Shin
Hirota, Yoshio
Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study
title Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study
title_full Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study
title_fullStr Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study
title_full_unstemmed Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study
title_short Real-World Effectiveness of the mRNA COVID-19 Vaccines in Japan: A Case–Control Study
title_sort real-world effectiveness of the mrna covid-19 vaccines in japan: a case–control study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145554/
https://www.ncbi.nlm.nih.gov/pubmed/35632535
http://dx.doi.org/10.3390/vaccines10050779
work_keys_str_mv AT haramegumi realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy
AT furuetakeki realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy
AT fukuokamami realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy
AT iwanagakentaro realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy
AT matsuishieijo realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy
AT miiketoru realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy
AT sakamotoyuichiro realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy
AT mukainaoko realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy
AT kinugasayuki realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy
AT shigyomutsumi realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy
AT sonodanoriko realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy
AT tanakamasato realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy
AT araseyasuko realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy
AT tanakayosuke realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy
AT nakashimahitoshi realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy
AT irieshin realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy
AT hirotayoshio realworldeffectivenessofthemrnacovid19vaccinesinjapanacasecontrolstudy